TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

被引：12
|
作者：
Bruins, Wassilis S. C.
Zheng, Wenrou
Higgins, Jack P.
Willert, Erin K.
Newcomb, John
Dash, Ajeeta B.
Van de Donk, Niels W. C. J.
Zweegman, Sonja
Mutis, Tuna
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136928
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 8 条
  • [1] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model
    Noort, Willy A.
    Groen, Richard W. J.
    Raymakers, Reinier
    Aalders, Linda
    Hofhuis, Frans M.
    Van Kessel, Berris
    Van Velzen, Jeroen F.
    de Bruijn, Joost
    Yuan, Huipin
    van Bueren, Jeroen Lammerts
    Bloem, Andries C.
    Parren, Paul W. H. I.
    Lokhorst, Henk
    Mutis, Tuna
    Martens, Anton C. M.
    BLOOD, 2012, 120 (21)
  • [2] Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples
    Karvouni, Maria
    Zhou, Heyue
    Kathleen, Arnika
    Ma, Qiangzhong
    Baloch, Alamdar H.
    Zhu, Tong
    Zhang, Hong
    Gilljam, Mari
    Lundqvist, Andreas
    Kaufmann, Gunnar F.
    Alici, Evren
    BLOOD, 2019, 134
  • [3] Anti-cancer activity of Biochanin A against multiple myeloma by targeting the CD38 and cancer stem-like cells
    Jaina, Vinod Kumar
    Eedara, Abhisheik
    Priya, S. V. S. Sasi
    Jadav, Surender Singh
    Chilaka, Sabarinadh
    Sistla, Ramakrishna
    Andugulapati, Sai Balaji
    PROCESS BIOCHEMISTRY, 2022, 123 : 11 - 26
  • [4] Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138
    van der Schans, Jort J.
    Wang, Ziyu
    van Arkel, Jennemiek
    van Schaik, Thijs
    Katsarou, Afroditi
    Ruiter, Ruud
    Baardemans, Thomas
    Yuan, Huipin
    de Bruijn, Joost
    Zweegman, Sonja
    van de Donk, Niels W. C. J.
    Groen, Richard W. J.
    Themeli, Maria
    Mutis, Tuna
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4219 - 4229
  • [5] A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells
    Rossi, Ann Marie
    Bunin, Anna
    Iben, Lawrence
    Welsch, Matthew
    Berbasova, Tanya
    Riillo, Caterina
    Rossi, Marco
    Ohuchi, Masaki
    Alvarez, Enrique
    Kawakami, Naoko
    Nagasawa, Takayuki
    Tassone, Pierfrancesco
    Spiegel, David
    Rastelli, Luca
    BLOOD, 2019, 134
  • [6] Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the Treatment of Multiple Myeloma
    Duggal, Rohit
    Sen Santara, Sumit
    Gordon, Myra
    Kilgallon, Aoife
    Hermanson, David
    Childs, Richard W.
    O'Dwyer, Michael E.
    BLOOD, 2021, 138
  • [7] A novel anti-CD37 antibody shows superior antibody dependent cellular cytotoxic activity, (ADCC) compared to Rituximab against patient-derived lymphoma cells
    Wu, H. S.
    Lunter, A-K
    Spillner, E.
    Schmitz, N.
    Heider, K-H
    Zeis, M.
    ONKOLOGIE, 2013, 36 : 134 - 134
  • [8] Attenuated Interferon-α Targeted to CD38 Expressing Multiple Myeloma Tumor Cells Induces Robust and Durable Anti-Tumor Responses through Direct Anti-Proliferative Activity in Addition to Indirect Recruitment and Activation of M1 Macrophages
    Pogue, Sarah
    Bi, Mingying
    Armanini, Mark
    Fatholahi, Marjan
    Taura, Tetsuya
    Valencia, Miriam
    Yun, Yong
    Sho, Angela
    Jamin, Anita
    Nock, Steffen
    Wilson, David S.
    BLOOD, 2017, 130
1